肠道微生物影响免疫检查点抑制剂及相关不良事件的最新研究进展  

Effects of gut microbiome on immune checkpoint inhibitor and related adverse events:research advances

作　　者：包云丽 唐海茹 王盼 李斌 于晓辉 BAO Yunli;TANG Hairu;WANG Pan;LI Bin;YU Xiaohui(Department of Gastroenterology,the 940th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army,Lanzhou,Gansu 730050,China;不详)

机构地区：[1]中国人民解放军联勤保障部队第九四〇医院,甘肃兰州730050 [2]甘肃中医药大学第一临床医学院

出　　处：《中国微生态学杂志》2024年第10期1219-1222,1227,共5页Chinese Journal of Microecology

基　　金：甘肃省青年科技基金项目(21JR7RA012);甘肃省科技厅社发处临床医学研究中心建设项目(21JR7RA017);第九四〇医院肝病临床医学研究中心培育项目(2021yxky079)。

摘　　要：人类肠道微生物群是复杂的肠道微生态系统的组成部分,可以介导宿主与肠道环境的相互作用,调节宿主局部和全身免疫反应,改变免疫药物的疗效和毒性。免疫检查点抑制剂(ICI)作为一种新型的抗肿瘤药物,在抗肿瘤方面取得了突破性的进展,为进展期和晚期恶性肿瘤患者带来了新的希望,但仍有部分患者存在响应率低和耐药等问题。同时,ICI还引入了一种全新的毒性谱,即免疫相关不良事件(irAEs),限制了ICI的广泛临床应用。因此,本文重点从肠道微生物组成、代谢产物对ICI和irAEs的影响以及肠道微生物与ICI相关的基础和临床研究现状作一简要综述,以期为ICI的临床应用提供更多参考。The human gut microbiome is a complex ecosystem that mediates host-intestinal environment interactions,regulates the host's local and systemic immune system,and alters the efficacy and toxicity of immune drugs.As a new type of anti-tumor drug,immune checkpoint inhibitor(ICI) have made breakthrough progress in anti-tumor therapy,bringing new hope to patients with progressive and advanced cancer.However,some patients still have the problems of low response rate and drug resistance.At the same time,ICI also introduce a new toxicity spectrum,namely immune-related adverse events(irAEs),which limits the extensive clinical application of ICI.Therefore,this paper intended to briefly review the composition of intestinal microbes and effects of their metabolites on ICI and irAEs,as well as current status of basic and clinical studies related to intestinal microbes and ICI,in order to provide more references for clinical treatment.

关 键 词：肠道微生物 免疫检查点抑制剂 免疫相关不良事件 

分 类 号：R459.9[医药卫生—治疗学]